GlassScriptPhysician profile
Sharon A Glick
NPI 1114911419
$14,367.98
in general payments reported to CMS, 2019-2025
33 companies · $1,455 in 2025
The $1,455 reported for 2025 was more than what a typical Pediatric Dermatology provider received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,900 · 2020: $1,987 · 2021: $428 · 2022: $386 · 2023: $819 · 2024: $1,394 · 2025: $1,455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,568 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,567.82 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pierre Fabre Pharmaceuticals, INC. | $7,158.71 | 2019 | |
| Genzyme Corporation | $1,836.89 | 2019-2025 | |
| Janssen Biotech, INC. | $866.21 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $737.46 | 2019-2025 | |
| Pfizer INC. | $581.76 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $312.69 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $291.05 | 2019-2025 | |
| Abbvie INC. | $259.41 | 2020-2025 | |
| Incyte Corporation | $256.54 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $220.69 | 2024-2025 | Nemluvio |
| Lilly USA, LLC | $176.05 | 2019-2025 | Ebglyss, Olumiant |
| Almirall LLC | $149.51 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $146.13 | 2021-2025 | Valchlor |
| Krystal Biotech INC | $132.43 | 2024-2025 | Vyjuvek |
| E.R. Squibb & Sons, L.L.C. | $129.19 | 2024-2025 | Sotyktu |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $115.44 | 2023-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $95.08 | 2020-2025 | Dupixent |
| Nobelpharma America, LLC | $93.01 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $91.45 | 2023-2025 | Zoryve |
| Mallinckrodt Hospital Products INC. | $82.03 | 2025 | Acthar |
| Sanofi-Aventis U.S. LLC | $81.19 | 2019-2021 | |
| Ucb, INC. | $78.92 | 2021-2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.53 | 2023-2025 | Spevigo |
| Dermavant Sciences, INC. | $70.87 | 2023-2024 | Vtama |
| Chiesi USA, INC. | $55.65 | 2024 | Filsuvez |
| Kyowa Kirin, INC. | $48.73 | 2021 | |
| Amgen INC. | $46.96 | 2023-2025 | Amjevita |
| Organon LLC | $45.14 | 2025 | Vtama |
| Botanix Sb INC | $37.28 | 2025 | Sofdra |
| Vyne Pharmaceuticals INC. | $29.91 | 2021 | |
| Lnhc, INC | $26.67 | 2025 | Zelsuvmi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.57 | 2020 | |
| Dermira, INC. | $14.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Glick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.